Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy
Molecular Therapy · 2023
DOI: 10.1016/j.ymthe.2023.07.021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2023. Verfasst von Kang Sun und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China; Zh…. Hauptthemen laut MEDLINE: Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Carcinoma, Pancreatic Ductal, B7-H1 Antigen, CD8-Positive T-Lymphocytes. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) is not sensitive to immune checkpoint blockade therapy, and negative feedback of tumor immune evasion might be partly responsible. We isolated CD8+ T cells and cultured them in vitro. Proteomics analysis was performed to compare changes in Panc02 cell lines cultured with conditioned medium, and leucine-rich repeat kinase 2 (LRRK2) was identified as a differential gene. LRRK2 expression was related to CD8+ T cell spatial distribution in PDAC clinical samples and upregulated by CD8+ T cells via interferon gamma (IFN-γ) simulation in vitro. Knockdown or pharmacological inhibition of LRRK2 activated an anti-pancreatic cancer immune response in mice, which meant that LRRK2 acted as an immunosuppressive gene. Mechanistically, LRRK2 phosphorylated PD-L1 at T210 to inhibit its ubiquitination-mediated proteasomal degradation. LRRK2 inhibition attenuated PD-1/PD-L1 blockade-mediated, T cell-induced upregulation of LRRK2/PD-L1, thus sensitizing the mice to anti-PD-L1 therapy. In addition, adenosylcobalamin, the activated form of vitamin B12, which was found to be a broad-spectrum inhibitor of LRRK2, could inhibit LRRK2 in vivo and sensitize PDAC to immunotherapy as well, which potentially endows LRRK2 inhibition with clinical translational value. Therefore, PD-L1 blockade combined with LRRK2 inhibition could be a novel therapy strategy for PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China; Zhejiang Provincial Key Laboratory of Pancreatic Disease, First Affiliat…
Zitieren
APA
Sun, K., Zhang, X., Lao, M., He, L., Wang, S., Yang, H., Xu, J., Tang, J., Hong, Z., Song, J., Guo, C., Li, M., Liu, X., Chen, Y., Zhang, H., Zhou, J., Lin, J., Zhang, S., Hong, Y., …, & Bai, X. (2023). Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2023.07.021
Vancouver
Sun K, Zhang X, Lao M, He L, Wang S, Yang H, et al. Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy. Molecular Therapy. 2023. doi:10.1016/j.ymthe.2023.07.021
BibTeX
@article{Sun2023,
author = {Sun, Kang and Zhang, Xiaozhen and Lao, Mengyi and He, Lihong and Wang, Sicheng and Yang, Hanshen and Xu, Jian and Tang, Jianghui and Hong, Zhengtao and Song, Jinyuan and Guo, Chengxiang and Li, Muchun and Liu, Xinyuan and Chen, Yan and Zhang, Hanjia and Zhou, Jingxing and Lin, Jieru and Zhang, Sirui and Hong, Yifan and Huang, Jinyan and Liang, Tingbo and Bai, Xueli},
title = {Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy},
journal = {Molecular Therapy},
year = {2023},
doi = {10.1016/j.ymthe.2023.07.021}
}
EUVIMED